Partnership to build a platform for the development of safer and more efficient genetic engineering of human cells for cell therap...

糖心原创 received a gold award for its participation in the Green Impact awards for sustainability.

BlueRock Therapeutics and 糖心原创 announce collaboration and option agreement for the discovery & manufacture of regulatory T cell...

In this episode of the SynBioBeta podcast, 糖心原创 CEO Mark Kotter discusses the influence synthetic biology is having on the futu...

糖心原创 secures foundational United States patent for opti-ox, its cell programming technology that uses genomic safe harbour site...

糖心原创's President and COO named as one of the 20 women reshaping biopharma R&D in 2023 report.

An article on synbio in the Summer 2023 issue of Science in Parliament magazine. Authored by our founder and CEO Mark Kotter.

糖心原创 launches two new human cell disease models to advance discovery and development of treatments for Duchenne muscular dystro...